News

Find News

Filter articles

Applied Filters

Showing 51 to 60 of 894 results

California mulls state generics brand

US13-01-2020Rory O'Neill

California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.

Judge refuses to block pay-for-delay law pending appeal

US13-01-2020Sarah Morgan

A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.

Senju, Bausch settle eye drop litigation against Indian generics maker

US09-01-2020Rory O'Neill

Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.

Fed Circuit issues mixed Sensipar verdict for Amgen

US09-01-2020Sarah Morgan

In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.

Allergan agrees to pay $300m to end birth control litigation

US08-01-2020Sarah Morgan

Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

Judge approves $120m Momenta and Sandoz settlement

US06-01-2020Rory O'Neill

A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

Generics makers appeal pay-for-delay ban to Ninth Circuit

US03-01-2020Rory O'Neill

A group of generics manufacturers yesterday, December 2 asked the US Court of Appeals for the Ninth Circuit to reverse California’s ban on pay-for-delay deals.

Adamas settles Gocovri clash with Sandoz

US03-01-2020Sarah Morgan

California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.

Eli Lilly secures Alimta patent win over Apotex

US02-01-2020Rory O'Neill

Eli Lilly has won a victory in a cancer drug dispute after a federal judge ruled that Canadian pharmaceutical company Apotex’s new drug application infringed the company’s patent.

Sandoz and Momenta to pay $120m to end antitrust suit

US24-12-2019Sarah Morgan

Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Showing 51 to 60 of 894 results

LSIPR